最新医学別冊　新しい診断と治療のABC74/神経5　てんかん

出版社： 最新医学社
発行日： 2012-07-25
分野： 臨床医学：一般  >  雑誌
ISSN： 03708241
雑誌名：
特集： てんかん
電子書籍版： 2012-07-25
書籍・雑誌
≪全国送料無料でお届け≫
品切れ

5,500 円(税込)

電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

4,400 円(税込)

購入する

目次

  • 最新医学別冊　新しい診断と治療のABC74/神経5　てんかん

    ―目次―

    特集　てんかん

    第１章　概念・定義、疫学、分類
    　世界の動向 　
    　概念・定義 　
    　疫学 　
    　分類 　

    第２章　病理・病態生理
    　病態生理 　
    　病因 　
    　病理　

    第３章　診断
    　診断 　
    　検査所見 　
    　画像所見 　
    　鑑別診断 　
    　遺伝子診断　

    第４章　治療・管理
    　コンプライアンス・日常生活指導 　
    　成人てんかん薬物療法　
    　小児・思春期てんかん薬物療法 　
    　高齢者てんかん 　
    　難治てんかん 　
    　てんかん重積状態 　
    　抗てんかん薬の副作用　
    　妊娠可能な女性てんかん　
    　心因性発作と精神症状
    　補助療法（ケトン食等） 　
    　外科治療 　
    　迷走神経刺激療法 　
    　経過・予後・治療の終結 　
    　災害時の対応 　
    　福祉・医療制度 　
    　自動車運転免許 　

    第５章　ガイドライン
    　ガイドライン

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第1章 概念・定義, 疫学, 分類

P.20 掲載の参考文献
1) Solomon L, et al:The International League Against Epilepsy at the threshold of its second century:Year 2. Epilepsia 53:215-219, 2012.
 
2) European Declaration on Epilepsy October 25, 1998. Epilepsia 44(s6):2-3, 2003.
 
3) www.ilae.org
 
4) www.ibe-epilepsy.org
 
5) Wiebe S, et al:A randomized, controlled trial of surgery for temporal-lobe epilepsy. N Engl J Med 345:311-318, 2001.
 
P.30 掲載の参考文献
1) Engel JJr, et al:Introduction;what is epilepsy? Epilepsy:a comprehensive textbook vol1 (Engel JJr, et al, eds), pp1-7. Wolters Kluwer, Philadelphia, 2008.
 
2) 清野昌一, 他:てんかん症候群. 医学書院, 東京, 1999.
 
3) 「てんかん治療ガイドライン」作成委員会:てんかん治療ガイドライン2010. 医学書院, 東京, 2010.
 
4) Blume W T, et al:Glossary of descriptive terminology for ictal semiology:report of the ILAE task force on classification and terminology. Epilepsia 42 (9):1212-1218, 2001.
PubMed
5) Fisher R S, et al:Epileptic seizures and epilepsy:definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia 46(4):470-472, 2005.
PubMed
6) Gastaut H Clinical and electroencephalographical classification of epileptic disorders. Epilepsia 11(1):102-113, 1970.
 
7) Merlis J K:Proposal for an international classification of the epilepsies. Epilepsia 11(1):114-119, 1970.
PubMed
8) Commission on Classification and Terminology of th International League Against Epilepsy:Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 22 (4):489-501, 1981.
 
9) Commission on Classification and Terminology of th International League Against Epilepsy:Proposal for revised classification of epilepsies and epileptic syndrome. Epilepsia 30(4):389-399, 1989.
 
10) 池田昭夫, 他:てんかんの国際分類「症状群・症候群」から「疾患」へ, 神経精神疾患 state of arts.医のあゆみver 1:648-651, 1999.
 
11) Engel JJr, et al A proposed diagnostic scheme for people with epileptic seizures and with epilepsy:report of the ILAE Task Force on Classification and Terminology. Epilepsia 42(6):796-803, 2001.
 
12) Engel JJr:Report of the ILAE classification core group. Epilepsia 47 (9):1558-1568, 2006.
 
13) 木下真幸子, 他:てんかん分類の最新の話題:脳波と症状の基軸からの発展をめざして.医のあゆみ 232(10):1021-1030, 2010.
Medical*Online
14) Berg A T, et al:Revised terminology and concepts for organization of seizures and epilepsies:report of the ILAE Commission on Classification and Terminology, 2005-2009, Epilepsia 51(4):676-685, 2010.
PubMed
15) Berg A T, et al:New concepts in classification of the epilepsies:Entering the 21stcentury. Epilepsia 52(6):1058-1062, 2011.
 
16) 池田昭夫:てんかんの基礎と臨床, てんかん発作とてんかん・てんかん症候群-その診断と分類.日医会誌 136:1078-1084, 2007.
 
17) Scheffer I E, et al Autsomal dominant nocturnal frontal lobe epilepsy. a distinct clinical disorder. Brain 118:61-73, 1995.
 
P.39 掲載の参考文献
1) Gastaut H, WHO & ILAE:Dictionary of Epilepsy (Part 1:Definitions) 1973. (和田豊治訳. てんかん事典. 金原出版, 1974.)
 
2) Sander J W:The epidemiology of epilepsy revisited. Curr Opin Neurol 16(2):165-170, 2003.
PubMed
3) Pedley T A, et al:Current practice of clinical electroencephalography, 3rd edition (Ebersole JS, ed), p506-518. Lippincott Williams & Wilkins, Philadelphia, 2003.
 
4) Tsuboi T:Prevalence and incidence of epilepsy in Tokyo. Epilepsia 29(2):103-110, 1988.
PubMed
5) Epilepsy Atlas, epilepsy care in the world, WHO, Switzerland, 2005.
 
6) Hauser W A, et al:Incidence and prevalence. In:Epilepsy:a comprehensive textbook, 2nd edition (Engel JJr, et al, eds), p45-56. Lippincott Williams & Wilkins, Philadelphia, 2008.
 
7) Kotsopoulos I A, et al:Systematic review and meta-analysis of incidence studies of epilepsy and unprovoked seizures. Epilepsia 43(11):1402-1409, 2002.
PubMed
8) Benn E K, et al:Estimating the incidence of first unprovoked seizure and newly diagnosed epilepsy in the low-income urban community Northern Manhattan, New York City. Epilepsia 49(8):1431-1439, 2008.
PubMed
9) Olafsson E, et al:Incidence of unprovoked seizures and epilepsy in Iceland and assessment of the epilepsy syndrome classification:a prospective study. Lancet Neurol 10:627-634, 2005.
PubMed
10) Hauser W A, et al:Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota:1935-1984. Epilepsia 34(3):453-468, 1993.
PubMed
11) Oun A, et al:Incidence of adult epilepsy in Estonia. Acta Neurol Scand 108:245-251, 2003.
PubMed
12) Cavazzuti G B, et al:Epidemiology of different types of epilepsy in school age children of Modena, Italy. Epilepsia 21:343-350, 1980.
 
13) Hauser W A, et al:Prevalence of epilepsy in Rochester, Minnesota:1940-1980. Epilepsia 32(4):429-445, 1991.
PubMed
14) Placencia M, et al:Epileptic seizures in an Andean region of Ecuador:incidence and prevalence variation. Brain 115:771-782, 1992.
 
15) Aziz H, et al:Epilepsy in Pakistan:a population-based epidemiologic study. Epilepsia 35:950-958, 1994.
PubMed
16) Berg A T, et al:The risk of seizure recurrence following a first unprovoked seizure:a quantitative review. Neurology 41(7):965-972, 1991.
PubMed
17) Sander J W, et al:The natural history and prognosis of epilepsy. In:Epilepsy:a comprehensive textbook, 2nd edition (Engel JJr, et al, eds), p65-70. Lippincott Williams & Wilkins, Philadelphia, 2008.
 
18) Van den B M, et al:Accidents in patients with epilepsy:types, circumstances, and complications:a European cohort study. Epilepsia 45(6):667-672, 2004.
 
19) Lhatoo S D, et al:Mortality. In:Epilepsy:a comprehensive textbook, 2nd edition(Engel JJr, et al, eds), p81-87. Lippincott Williams & Wilkins, Philadelphia, 2008.
 
20) Nashef L, et al:Sudden death in epilepsy:a study of incidence in a young cohort with epilepsy and learning difficulty. Epilepsia 36(12):1187-1194, 1995.
 
P.48 掲載の参考文献
1) WHO:Atlas:epilepsy care in the world. Genever World Health Organization, 2005.
 
2) Commission on classification and terminology of the ILAE:Clinical and electroencephalographic classification of epileptic seizure. Epilepsia 11:102-113, 1970.
 
3) Proposal for an international classification of epilepsies. Epilepsia 11:114-119, 1970.
PubMed
4) Commission on Classification and Terminology of the International League Against Epilepsy:Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 22:489-501, 1981.
PubMed
5) Commission on Classification and Terminology of the International League Against Epilepsy:Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 30:389-399, 1989.
PubMed
6) Berg A T, et al:Revised terminology and concepts of organization of seizures and epilepsies:Report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia 51:676-685, 2010.
PubMed
7) 重藤寛史, 他:てんかんの分類. Clin Neurosci 26:29-32, 2008.
 
8) 飛松省三, 他:てんかんの分類. <アクチュアル脳・神経疾患の臨床>「てんかんテキストNew Version」, p48-54, 中山書店, 東京, 2012.
 
9) 飛松省三, 他:てんかんの病型分類. <アクチュアル脳・神経疾患の臨床>「てんかんテキストNew Version」, p338-346, 中山書店, 東京, 2012.
 
10) 日本神経学会(監修):てんかん治療ガイドライン委員会. てんかん治療ガイドライン 2010. 医学書院, 東京, 2010.
 
11) 重藤寛史:てんかんの初期診療と最近のトピックス. 福岡医誌102:195-202, 2011.
 
12) 日本てんかん学会分類委員会:てんかん発作の臨床・脳波分類(1981). てんかん研 5:62, 1987.
 
13) 日本てんかん学会分類用語委員会(翻訳):てんかん発作およびてんかんを体系化するための用語と概念の改訂:ILAE分類・用語委員会報告(2005～2009年). てんかん研 28:515-525, 2011.
 
14) 木下真幸子, 他:てんかん分類の最新の話題-脳波と症状の基軸からの発展をめざして. 医のあゆみ 232:1021-1030, 2010.
Medical*Online

第2章 病理・病態生理

P.58 掲載の参考文献
1) 丸栄一, 他:てんかんの病態生理-抑制から発作へ-, 神研の進歩48(6):917-927, 2004.
 
2) Ben-Ari Y, et al:Excitatory Actions of GABA during development:the nature or the nurture. Nature Review. Neuroscience 3 (9):728-739, 2002.
PubMed
3) Staley K J, et al:Ionic mechanisms of neuronal excitation by inhibitory GABAA receptors. Science 269(5226):977-981, 1995.
PubMed
4) 丸栄一, 他:海馬後発射誘発に伴う反回性シナプス抑制の変化. 脳精医 1(1):111-116, 1990.
 
5) Maru E, et al:Alteration in dentate neuronal activities associated with perforant path kindling. III. Enhancement of synaptic inhibition. Exp Neurol 96:46-60, 1987.
PubMed
6) Tuff L P, et al:The effects of kindling on GABA-mediated inhibition in the dentate gyrus of the rat. II. Receptor binding. Brain Res 277:91-98, 1983.
PubMed
7) Fujita Y, et al:Spontaneous hyperpolarizations in pyramidal cells of chronically stimulated rabbit hippocampus. JPN J physiol 31:879-889, 1981.
PubMed
8) Engel J Jr, et al:Evidence for enhanced synaptic inhibition in epilepsy. In:Neurotransmitters, Seizures and epilepsy III (Nistico G, et al, eds), p1-13. Raven press, New York, 1986.
 
9) Engel J Jr, et al:Epileptic activation of antagonistic systems may explain paradoxical features of experimental and human epilepsy:a review and hypothesis. In:Kindling II (Wada JA, eds), p193-217. Raven press, New York, 1981.
 
10) Maru E, et al:Alteration in dentate neuronal activities associated with perforant path kindling. I. Long-term potentiation of excitatory synaptic potentiation. Exp Neurol 96:19-32, 1987.
 
11) Huberfeld G, et al:Perturbed chloride homeostasis and GABAergic signaling in human temporal lobe epilepsy. J Neurosci 27(37):9866-9873, 2007.
PubMed
12) Morris M E, et al:Extracellular K+ accumulations and synchronous GABA-mediated potentials evoked by 4-aminopyridine in the adult rat hippocampus. Exp Brain Res 109:71-82, 1996.
PubMed
13) Higashima M, et al:Involvement of GABAA and GABAB receptors in afterdischarge generation in rat hippocampal slices. Brain Res 865:186-193, 2000.
 
14) Van Vliet E A, et al:Blood-brain barrier leakage may lead to progression of temporal lobe epilepsy. Brain 130:521-534, 2007.
PubMed
15) Ivens S, et al:TGF-β receptor-mediated albumin uptake into astrocytes is involved in neocortical epileptogenesis. Brain 130:535-547, 2007.
 
16) Perea G, et al:Tripartite synapses, Astrocytes process and control synaptic information. Trend Neurosci 32:421-431, 2009.
PubMed
17) Tian G-F, et al:An astrocytic basis of epilepsy. Nature Med 11(9):973-981, 2005.
PubMed
18) Fellin T, et al:Neuronal synchrony mediated by astrocytic glutamate through activation of extrasynaptic NMDA receptors. Neuron 43:729-743, 2004.
PubMed
P.70 掲載の参考文献
1) 高橋幸利:てんかんの捉え方, 小児てんかん診療マニュアル改訂第2版増補版 (藤原建樹 監, 高橋幸利 編), pp2-8 診断と治療社, 東京, 2012.
 
2) Hauser WA, et al:Incidence of Epilepsy and unprovoked sezures in Rochester, Minnesota:1935-1984, Epilepsia 34(3):453-468, 1993.
 
3) Scheffer I E, et al:Neonatal epilepsy syndromes and generalized epilepsy with febrile seizures plus (GEFS+). Epilepsia 46(Suppl 10):41-47, 2005.
 
4) Ottman R, et al:Genetic testing in the epilepsies-Report of the ILAE Genetics Commission, Epilepsia 51(4):655-670, 2010.
PubMed
5) Marini C, et al:The genetics of Dravet syn-drome. Epilepsia 52(Supp12):24-29, 2011.
 
6) Ogiwara I, et al:Nav1.1 Localizes to Axons of Parvalbumin-Positive Inhibitory Interneurons:A Circuit Basis for Epileptic Seizures in Mice Carrying an Scnla Gene Mutation. J Neurosci 27(22):5903-5914, 2007.
PubMed
7) Okumura A, et al:Acute encephalopathy in children with Dravet syndrome. Epilepsia 53(1):79-86, 2012.
PubMed
8) Saitsu H, et al:STXBPI mutations in early infantile epileptic encephalopathy with suppression-burst pattern. Epilepsia 51(12):2397-2405, 2010.
PubMed
9) Mastrangelo M, et al:Genes of early-onset epileptic encephalopathies:from genotype to phenotype. Pediatr Neurol 46(1):24-31, 2012.
PubMed
10) Jeyifous O, et al:SAP97 and CASK mediate sorting of NMDA receptors through a previously unknown secretory pathway. Nat Neurosci 12(8):1011-1019, 2009.
PubMed
11) Blumcke I, et al:Malformations of cortical development and epilepsies:neuropathological findings with emphasis on focal cortical dysplasia. Epileptic Disord 11(3):181-193, 2009.
PubMed
12) Takase K, et al:Prenatal freeze lesioning produces epileptogenic focal cortical dysplasia. Epilepsia 49(6):997-1010, 2008.
PubMed
13) Ying Z, et al:Increased Numbers of Coassembled PSD-95 to NMDA-receptor Subunits NR2B and NRI in Human Epileptic Cortical Dysplasia. Epilepsia 45 (4):314-321, 2004.
 
14) Iyer A, et al:Evaluation of the innate and adaptive immunity in type I and type II focal cortical dysplasias. Epilepsia 51 (9):1763-1773, 2010.
PubMed
15) D'Antuono M, et al:GABAA receptor-dependent synchronization leads to ictogenesis in the human dysplastic cortex. Brain 127:1626-1640, 2004.
 
16) Mathern G W, et al:Human hippocampal AMPA and NMDA mRNA levels in temporal lobe epilepsy patients. Brain 120:1937-1959, 1997.
PubMed
17) Holmes G L:Epilepsy in the Developing Brain:Lessons from the Laboratory and Clinic. Epilepsia 38(1):12-30, 1997.
PubMed
18) 高橋幸利, 他:小児疾患診療のための病態生理2, てんかん. 小児内増刊号41:728-734, 2009.
 
19) 大森京子, 他:てんかん発現の分子機構:難治性てんかん治療薬開発に向けて. 日薬理誌 114:161-168, 1999.
 
20) Lee WT, et al:Risk factors for postencephalitic epilepsy in children:A hospital-based study in Taiwan. Eur J paediat Neurol 11:302-309, 2007.
 
21) Pisani F, et al:Development of epilepsy in newborns with moderate hypoxic-ischemic encephalopathy and neonatal seizures. Brain Dev 31(1):64-68, 2009.
PubMed
22) Aetiology of Epilepsy, Epilepsia 44(Suppl. 6):21-22, 2003.
 
P.82 掲載の参考文献
1) Bozzi Y, et al:Epilepsy as a neurodevelopmental disorder. Frontiers in Psychiatry 3:doi:10.3389/fpsyt.2012.00019, 2012
 
2) Kramer U, et al:Epidemiology of epilepsy in childhood:a cohort of 440 consecutive patients. Pediatr Neurol 18:46-50, 1998.
PubMed
3) Raymond A A, et al:Abnormalities of gyration, heterotopias, tuberous sclerosis, focal cortical dysplasia, microdysgenesis, dysem-bryoplastic neuroepithelial tumour and dysgenesis of the archicortex in epilepsy. Clinical, EEG and neuroimaging features in 100 adult patients. Brain 118:629-660, 1995.
 
4) Meroni A, et al:Nodular heterotopia:a neuropathological study of 24 patients undergoing surgery for drug-resistant epilepsy. Epilepsia 50:116-124, 2009.
PubMed
5) Blumcke I, et al:The clinicopathologic spectrum of focal cortical dysplasias:A consensus classification proposed by an ad hoc task force of the ILAE diagnostic methods commission. Epilepsia 52(1):158-174, 2011.
 
6) Aronica E, et al:Malformations of cortical development Brain Pathol 22(2):380-401, 2012.
 
7) Manoranjan B, et al:Hemimegalencephaly:a fetal case with neuropathological comfirmation and review of the literature. Acta Neuropathol 120:117-130, 2010.
 
8) Manzini M C, et al:What disorders of cortical development tell us about the cortex:one plus one does not always make two. Curr Opin Genet Dev 21(3):333-339, 2011.
 
9) Lian G, et al:Cerebral developmental disorders. Curr Opin Pediatr 18(6):614-620, 2006.
PubMed
10) Thom M, et al:Reliability of patterns of hippocampal sclerosis as predictors of post surgical outcome. Epilepsia 51(9):1801-1808 2010.
 
11) Blumcke I, et al:Defining clinico-neuropathological subtypes of mesial temporal lobe epilepsy with hippocampal sclerosis. Brain Pathol 22(2):402-411, 2012.
 
12) Bien C G, et al:Pathogenesis, diagnosis and treatment of Rasmussen encephalitis. A European consensus statement. Brain 128:454-471, 2005.
PubMed
13) Kwaitakowski D J:Tuberous sclerosis:from tuber to mTOR. Ann Hum Genet 67:87-96, 2003.
 
14) Orlova K A, et al:The tuberous sclerosis complex. Ann NY Acad Sci 1184:87-105, 2010.
PubMed

第3章 診断

P.91 掲載の参考文献
1) 飯沼一宇, 他:てんかんの診断ガイドライン. てんかん研 26(1):110-113, 2008.
 
2) Stokes T, et al:Clinical Guidelines and Evidence Review for the Epilepsies:diagnosis and management in adults and children in primary and secondary care. P49-50, 85-95, Royal College of General Practitioners, London, 2004.
 
3) 高橋幸利:てんかんの診断から治療の流れ. 小児てんかん診療マニュアル. (藤原建樹 監), p17-23, 診断と治療社, 東京, 2010.
 
4) National Association of Epilepsy Centers:Guidelines for essential services, personnel, and facilities in specialized epilepsy centers in the United States. Epilepsia 42:804-814, 2001.
PubMed
5) 花井敏男:けいれんとけいれん類似症状との鑑別. 小児内科 31(4):455-459, 1999.
 
6) 辻貞俊:成人においててんかんと鑑別されるべき疾患はなにか. てんかん治療ガイドライン2010. (日本神経学会監修), p8-11. 医学書院, 東京, 2010.
 
7) Commission on Classification and Terminology of the International League Against Epilepsy:Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 30:389-399, 1989.
PubMed
8) Commission on Classification and Terminology of the International League Against Epilepsy:Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 22:489-501, 1981.
PubMed
9) 兼本浩祐, 他:心因性非てんかん発作 (いわゆる偽発作) に関する診断・治療ガイドライン. てんかん研26(3):478-482, 2009.
 
P.101 掲載の参考文献
1) Autret A, et al:Influence of waking and sleep stages on the inter-ictal paroxysmal activity in partial epilepsy with complex seizures. Electroenceph clin Neurophysiol 55:406-410, 1983.
PubMed
2) Kellaway P:Sleep and epilepsy. Epilepsia 26 (Suppl 1):S15-30, 1985.
 
3) Shouse M N, et al:Physiological basis:how NREM sleep components can promote and REM sleep components can suppress seizure discharge propagation. Clin Neurophysiol 111 (Suppl 2):S9-Sl8, 2000.
PubMed
4) Wirrell E C:Prognostic significance of interictal epileptiform discharges in newly diagnosed seizure disorders. J Clin Neurophysiol 27:239-248, 2010.
PubMed
5) Martins da Silva A, et al:The circadian distribution of interictal epileptiform EEG activity. Electroencephalogr Clin Neurophysiol 58:1-13, 1984.
PubMed
6) Spencer S S, et al:Interictal spikes on intracranial recording:behavior, physiology, and implications. Epilepsia 49:1881-1892, 2008.
PubMed
7) 日本神経学会:てんかん治療ガイドライン (「てんかん治療ガイドライン」作成委員会編), pp8-9. 医学書院, 東京, 2010.
 
8) Vincent A, et al:Systemic and neurologic autoimmune disorders associated with seizures or epilepsy. Epilepsia 52(Suppl 3):12-17, 2011.
 
9) Schiess N, et al Hashimoto's encephalopathy. Ann N Y Acad Sci 1142:254-265, 2008.
 
10) 紀田康雄, 他:意識消失発作で神経内科外来通院中に発見されたインスリノーマの1例. Diabetes Frontier 5:623-628, 2005.
Medical*Online
11) 重藤寛史:てんかんの初期診療と最近のトピックス. 福岡医誌 102:195-202, 2011.
Medical*Online
12) 重藤寛史:神経内科医としてのてんかん診療臨神経51:661-668, 2011.
 
13) Iwasaki M, et al:Detection of epileptiform activity by human interpreters:blinded comparison between electroencephalography and magnetoencephalography. Epilepsia 46:59-68, 2005.
PubMed
14) 重藤寛史, 他:てんかんに対するルーチン検査としての脳磁図の有用性と限界. 臨脳波 51:626-631, 2009.
Medical*Online
15) 重藤寛史, 他:てんかんのビデオ脳波モニタ. 医のあゆみ232:1050-1055, 2010.
 
P.109 掲載の参考文献
1) 飯沼一宇:てんかんの診断ガイドライン. てんかん研究 26(1):110-113, 2008.
 
2) Gaillard W D, et al:Guidelines for imaging infants and children with recent-onset epilepsy. Epilepsia 50(9):2147-2153, 2009.
PubMed
3) Spencer S S:MRI and Epilepsy Surgery. Neurology 45(7):1248-1250, 1995.
PubMed
4) Luders H, et al:Conceptual considerations. In:Epilepsy Surgery (Luders H, Eds), p51-62. Raven Press, New York, 1992.
 
5) 前原健寿:術前検査の画像化による焦点診断とてんかん手術. Neurol Surg 35(11):1053-1065, 2007.
 
6) Taylor D C, et al:Focal dysplasia of the cerebral cortex in epilepsy. J Neurol Neurosurg Psychiatry 34(4):369-387, 1971.
 
7) Meencke H J, et al:Neuropathological findings in primary generalized epilepsy:a study of eight cases. Epilepsia 25(1):8-21, 1984.
PubMed
8) Mischel P S, et al:Cerebral cortical dysplasia associated with pediatric epilepsy. Review of neuropathologic features and proposal for a grading system. J Neuropathol Exp Neurol 54(2):137-153, 1995.
PubMed
9) Palmini A, et al:Terminology and classification of the cortical dysplasias. Neurology 62(6 Suppl 3):S2-8, 2004.
 
10) Blumcke I, et al:The clinicopathologic spectrum of focal cortical dysplasias:a consensus classification proposed by an ad hoc Task Force of the ILAE Diagnostic Methods Commission Epilepsia 52(1):158-174, 2011.
 
11) Carne R P, et al:MRI-negative PET-positive temporal lobe epilepsy:a distinct surgically remediable syndrome. Brain 127 (10):2276-2285, 2004.
 
12) Schramm J, et al:Surgery for temporal mediobasal tumors:experience based on a series of 235 patients, Neurosurgery 62 (6 Suppl 3):1272-1282, 2008.
PubMed
13) Stavrou I, et al:Long-term seizure control after resection of supratentorial cavernomas:a retrospective single-center study in 53 patients. Neurosurgery 63(5):888-896, 2008.
PubMed
14) Englot D J, et al:Predictors of seizure freedom in the surgical treatment of supratentorial Cavernous malformations. J Neurosurg 115(6):1169-1174, 2011.
PubMed
15) Briellmann RS, et al:MR imaging of epilepsy:State of the art at 1.5 T and potential of 3 T. Epileptic Disorders 5(1):3-20, 2003.
PubMed
P.118 掲載の参考文献
1) てんかん治療ガイドライン作成委員会:てんかん治療ガイドライン2010, p9-11.医学書院, 東京, 2010.
 
2) 大石実:脳波の判読 DVD-Video 付, p1-95. 中外医学社, 東京, 2002.
 
3) 大石実:急性症候性発作. Clin Neurosci 29:97-99, 2011.
 
4) Beghi E, et al:Recommendation for a definition of acute symptomatic seizure. Epilepsia 51(4):671-675, 2010.
PubMed
5) Bolaman Z, et al:Takayasu arteritis with intracranial involvement mimicking epilepsy:case report and review of the literature. Intern Med 50:1345-1348, 2011.
PubMed
6) Irani S R, et al:NMDA receptor antibody encephalitis. Curr Neurol Neurosci Rep 11:298-304, 2011.
PubMed
7) Gratton D, et al:Reversible posterior leukoencephalopathy syndrome in a patient treated with ustekinumab;case report and review of the literature. Arch Dermatol 147 (10):1197-1202, 2012.
 
8) Benbadis S:The differential diagnosis of epilepsy:A critical review. Epilepsy Behavior 15:15-21, 2009.
PubMed
9) Duncan R:Psychogenic nonepileptic seizures:diagnosis and initial management Expert Rev Neurother 10(12):1803-1809, 2010.
PubMed
10) Capovilla G, et al:Recommendations for the management of "febrile seizures", Epilepsia 50(Suppl 1):2-6, 2009.
 
11) Mendonca de Siqueira L F:Febrile seizures update on diagnosis and management Rev Assoc Med Bras 56(4):489-492, 2010.
 
12) Thijs R D, et al:Falls, faints, fits and funny turns. J Neurol 256:155-167, 2009.
 
13) 合同研究班:失神の診断・治療ガイドライン. Circulation J 71(Suppl IV):1049-1101, 2007.
 
14) The Task Force for the Diagnosis and Management of Syncope of the European Society of Cardiology(ESC):Guidelines for the diagnosis and management of syncope (version 2009). Europ Heart J 30:2631-2671, 2009.
 
P.124 掲載の参考文献
1) Morimoto M, et al:SCNIA mutation mosaicism in a family with severe myoclonic epilepsy in infancy. Epilepsia 47:1732-1736,2006.
 
2) Mullen S A, et al:Translational research in epilepsy genetics:sodium channels in man to interneuronopathy in mouse. Arch Neurol 66:21-26, 2009.
 
3) Hattori J, et al:Ascreening test for the prediction of Dravet syndrome before one year of age. Epilepsia 49:626-633, 2008.
 
4) Stafstrom C E:Sever epilepsy syndrome of early childhood:the link between genetics and pathophysiology with a focus on SCNIA mutation& J Child Neurol 24:15S-23S, 2009.
 
5) Singh N A, et al:A novel potassium channel gene, KCNQ2, is mutated in an inherited epilepsy of newborns. Nat Genet 18:25-29, 1998.
 
6) Hirose S, et al:A novel mutation of KCNQ3 (c.925T->C) in a Japanese family with benign familial neonatal convulsions. Ann Neurol 47:822-826, 2000.
 
7) Singh N A, et al:KCNQ2 and KCNQ3 potassium channel genes in benign familial neonatal convulsions:expansion of the functional and mutation spectrum. Brain 126:2726-2737, 2003.
PubMed
8) Kurahashi H, et al:Deletions involving both KCNQ2 and CHRNA4 present with benign familial neonatal seizures. Neurology 73:1214-1217, 2009.
PubMed
9) Medina M T, et al:Novel mutations in Myoclonin1/EFHC1 in sporadic and familial juvenile myoclonic epilepsy. Neurology 70:2137-2144, 2008.
PubMed
10) Kaneko S, et al:Development of Individualized Medicine for Epilepsy Based on Genetic Information. Expert Rev Clin Pharmacol 1:661-681, 2008.
 
11) 兼子直, 他:てんかんに対する新たな治療法開発と標準化に関する研究. 精神・神経疾患研究委託費総括研究報告書(19指-6):81-84, 2010.
 
12) Blumenfeld H, et a1:Early treatment suppresses the development of spike-wave epilepsy in a rat model Epilepsia 49:400-409, 2008.
 

第4章 管理・治療

P.133 掲載の参考文献
1) アリソン・ブレンキンソップ:処方後の患者サポート. なぜ, 患者は薬を飲まないのか? (クリスティーヌ・ボンド編), p91-111. 薬事日報社, 東京, 2010.
 
2) ウィリアム・H・セオドア,他:怠薬は,難治発作のよくある原因の1つである.てんかん診療第3版,p119-123.メディカル・サイエンス・インターナショナル,東京,1996.
 
3) 笹川睦男:1回分の服薬を忘れてしまった時の対処法は? てんかん診療のクリニカルクエスチョン194, p168-169. 診断と治療社, 東京, 2009.
 
4) 静岡医療センター薬剤科:上手な薬の飲み方, 飲ませ方. 日常生活のためのてんかんのくすり (日本てんかん協会編), p134-136. 日本文化科学社, 東京, 2003.
 
5) 渡辺裕貴:発作のおこりやすい誘因とは? 自己誘発発作とは? てんかん診療のクリニカルクエスチョン194, p64-65. 診断と治療社, 東京, 2009.
 
6) WILLIAM GORDON LENNOX:Figure 189, EPILEPSY and Related Disorders volume two P820. LITTLE, BROWN AND COMPANY, LONDON, 1960.
 
7) 渡辺裕貴:発熱時に発作は増える? 発作時の治療は? てんかん診療のクリニカルクエスチョン194(松浦雅人編) p65-66.診断と治療社, 東京, 2009.
 
8) 兼子直:月経と妊娠.改訂てんかん教室, p84. 新興医学出版社, 東京, 2003.
 
9) 八木和一:おふろ. 第13回てんかんセミナー, てんかんをもつひとの就労(国立療養所静岡神経医療センター主催), p13-14. 2004.
 
10) 冨澤江実子:入浴時の注意点は? てんかん診療のクリニカルクエスチョン194(松浦雅人編), p279-281. 診断と治療社, 東京, 2009.
 
11) 荒木聡:スポーツ活動への参加はどのように指導する? てんかん診療のクリニカルクエスチョン 194 (松浦雅人編), p286-287. 診断と治療社, 東京, 2009.
 
12) 荒木聡:学校でのプール参加はどのように指導する? 海水浴やマリンスポーツは? てんかん診療のクリニカルクエスチョン 194 (松浦雅人編), p282-283. 診断と治療社, 東京, 2009.
 
13) 古牧理恵子:教室外での指導場面での配慮について, 第10回てんかんセミナーてんかんをもつ児童・生徒の学校生活 (国立療養所静岡神経医療センター主催), p15. 2002.
 
14) 三宅捷太:水より怖いプールサイドのコンクリ<誰でも危険>.てんかん-その精神症状と行動 (松浦雅人, 他編), p190-192. 新興医学出版社, 東京, 2004.
 
15) 八木和一:旅行. 第13回てんかんセミナーてんかんをもつひとの就労 (国立療養所静岡神経医療センター主催), p14. 2004.
 
16) 渡辺雅子:こんなときどのようにしたらいいでしょうか? 日常生活のためのてんかんのくすり (日本てんかん協会編), p144-149. 日本文化科学社, 東京, 2003.
 
P.140 掲載の参考文献
1) Hauser W:Overview:Epidemiology, Pathology, and Genetics. In:Epilepsy:a comprehensive text book Vol.2 (Engel J Jr, et al, eds), pp9-11. Lippincott Williams & Wilkins, Philadelphia, 2007.
 
2) Fisher R S, et al:Epileptic seizures and epilepsy:definitions proposed by the International League Against Epilepsy(ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia 46:470-472, 2005.
PubMed
3) Berg A T, et al:The risk of seizure recurrence following a first unprovoked seizure:a quantitative review. Neurology 41:965-972, 1991.
PubMed
4) Hauser W A, et al:Seizure recurrence after a first unprovoked seizure. N Engl J Med 307:522-528, 1982.
PubMed
5) Hauser WA, et al:Risk of recurrent seizures after two unprovoked seizures. N Engl J Med 338:429-434, 1998.
PubMed
6) Krumholz A, et al:Practice Parameter:evaluating an apparent unprovoked first seizure in adults (an evidence-based review):report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 69:1996-2007, 2007.
PubMed
7) Ramsay R E, et al:Diagnosing epilepsy in the elderly. Int Rev Neurobiol 81:129-151, 2007.
PubMed
8) Kwan P, et al:Early identification of refractory epilepsy. N Engl J Med 342:314-319, 2000.
PubMed
9) Marson A, et al:Immediate versus deferred antiepileptic drug treatment for early epilepsy and single seizures:a randomised controlled trial. Lancet 365:2007-2013, 2005.
PubMed
10) Berg A T, et al:Revised terminology and concepts for organization of seizures and epilepsies:report of the ILAE Commissionon Classification and Terminology, 2005-2009. Epilepsia 51:676-685, 2010.
 
11) Marson A G, et al:The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy:an unblinded randomised controlled trial. Lancet 369:1000-1015, 2007.
 
12) Karceski S, et al:Treatment of epilepsy in adults:expert opinion, 2005. Epilepsy Behav 7(Suppl 1):S1-64:quiz S65-67, 2005.
 
13) Marson AG, et al:The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy:an unblinded randomised controlled tria1. Lancet 369:1016-1026, 2007.
 
14) Kanner A M:Psychogenic Nonepileptic Seizures Are Bad for Your Health. Epilepsy Curr 3:181-182, 2003.
PubMed
15) Krumholz A, et al:Psychogenic seizures:a clinical study with follow-up data. Neurology 33:498-502, 1983.
PubMed
16) Perucca E, et al:Antiepileptic drugs as a cause of worsening seizures. Epilepsia 39:5-17, 1998.
PubMed
17) Wallace S J:Newer antiepileptic drugs:advantages and disadvantages. Brain Dev 23:277-283, 2001.
PubMed
18) Chadwick D, et al:Outcomes after seizure recurrence in people with well-controlled epilepsy and the factors that influence it. The MRC Antiepileptic Drug Withdrawal Group. Epilepsia 37:1043-1050, 1996.
PubMed
P.153 掲載の参考文献
1) 須貝研司:薬物動態と血中濃度モニター. Clin Neurosci 29:42-47, 2011.
 
2) 須貝研司:抗てんかん薬. 小児内科 42:139-146, 2010.
 
3) Levy RH, et al:Antiepileptic Drugs, 5th ed. Lippincott Williams & Wilkins, Philadelphia, 2002.
 
4) Wyllie E, et al:The Treatment of Epilepsy:Principles and Practice, 4th ed. Lippincott Williams & Wilkins, Philadelphia, 2006.
 
5) Engel J Jr, et al:Epilepsy. A complehensive textbook 2nd ed. Vol 2. Wolters Kluwer/Lippincott Williams & Wilkins, Philadelphia, 2008.
 
6) Shorvon S, et al:The Treatment of Epilepsy 3rd ed. Wiley Blackwell, Chichester, UK, 2009.
 
7) Roger J, et al:Epileptic syndromes in infancy, childhood and adolescence 4th ed, John Libbey Eurotext, Montrouge, France, 2005.
 
8) 須貝研司:てんかんの治療. 国立精神・神経センター小児神経科診断・治療マニュアル改訂第2版(加我牧子, 他編), p276-287. 診断と治療社, 東京, 2009.
 
9) 須貝研司:重症心身障害児(者)のてんかんの薬物療法-抗てんかん薬の使い方の実際-. 日重症心身障害会誌 36:91-99, 2011.
 
10) http://guidance.nice.org.uk/the-epilepsies-th のAppendix E:Pharmacological treatment
 
P.161 掲載の参考文献
1) Hauser W A, et al:Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota:1935-1984. Epilepsia 34(3):453-468, 1993.
PubMed
2) Ramsay R E, et al:Special considerations in treating the elderly patient with epilepsy. Neurology 62(5)Suppl 2:S24-29, 2004.
 
3) 辻 貞俊:高齢者のてんかんに対する標準化治療に関する研究.てんかんに対する新たな治療法開発と標準化に関する研究 総括研究報告書:161-170, 2010.
 
4) Rowan A J, et al:New onset geriatric epilepsy:a randomized study of gabapentin, lamotrigine, and carbamazepine. Neurology 64(11):1868-1873, 2005.
PubMed
5) Drury I, et al:Interictal epileptiform activity in elderly patients with epilepsy. Electroencephalogr Clin Neurophysiol 106 (4):369-373, 1998.
PubMed
6) 神一敬他:てんかん診療におけるビデオ脳波モニタリングの意義. 神経内科 75(6):539-544, 2011.
 
7) McKeon A, et al:Seizure versus syncope. Lancet Neurol 5(2)171-180, 2006.
PubMed
8) Sheldon R, et al:Historical criteria that distinguish syncope from seizures. J Am Coll Cardiol 40(1):142-148, 2002.
PubMed
9) 赤松直樹他:高齢者のてんかん-病態,診断,その特殊性.医のあゆみ232(10):973-977, 2010.
 
10) 日本てんかん学会ガイドライン作成委員会報告.成人てんかんにおける薬物治療ガイドライン.てんかん研究23(3):249-253, 2005.
 
11) Ramsay R E, et al:Diagnosing epilepsy in the elderly. Int Rev Neurobio 181:129-151, 2007.
 
12) Kutluay E, et al:Safety and tolerability of oxcarbazepine in elderly patients with epilepsy. Epilepsy Behav 4(2):175-180, 2003.
PubMed
13) Cloyd J, et al:Epidemiological and medical aspects of epilepsy in the elderly. Epilepsy Res 68(Suppl 1):S39-48, 2006.
PubMed
14) Cameron H, et al:Anticonvulsant therapyy in elderly patients with epilepsy, a need for placebo controlled trials. Epilepsy Res 21(2):149-157, 1995.
PubMed
15) Brodie M J, et al:Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Res 37(1):81-87, 1999.
 
16) Saetre E, et al:An international multicenter randomized double-blind controlled trial of lamotrigine and sustained-release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly. Epilepsia 48(7):1292-1302, 2007.
PubMed
17) 日本てんかん学会ガイドライン作成委員会報告.高齢者のてんかんに対する診断・治療ガイドライン. (Online) available from <http://square.umin.ac.jp/jes/>.
 
18) てんかん治療ガイドライン2010.日本神経学会監修「てんかん治療ガイドライン」作成委員会編.p37.医学書院,東京, 2010.
 
19) Karceski S, et al:Treatment of epilepsy in adults:expert opinion, 2005. Epilepsy Behav 7(Suppl 1):Sl-64,2005.
 
20) 山野光彦,他:高齢者初発てんかんの治療に対するアンケート調査-エキスパートオピニオン研究-.てんかん研究28(1):17-23, 2010.
 
P.174 掲載の参考文献
1) Arts W F M, et al:Course and prognosis of childhood epilepsy:5-year follow-up of the Dutch study of epilepsy in childhood. Brain 127(8):1774-784, 2004.
 
2) Berg A T, et al:Defining intractability:comparisons among published definitions. Epilepsia 47(2):431-436, 2006.
PubMed
3) Ramos-Lizana J, et al:Early prediction of refractory epilepsy in childhood. Seizure 18(6):412-416, 2009.
PubMed
4) Callaghan B, et al:Remission and relapse in a drug-resistant epilepsy population followed prospectively. Epilepsia 52(3):619-626, 2011.
 
5) Kwan P, et al:Definition of drug resistant epilepsy:consensus proposal by the ad hoc Task Force of the ILAE commission on therapeutic strategies. Epilepsia 51(6):1069-1077, 2010.
 
6) 日本神経学会:てんかん治療ガイドライン 2010. 医学書院東京, 2010.
 
7) Kwan P, et al:Early identfication of refractory epilepsy. N Engl J Med 342(5):314-319, 2000.
 
8) Berg A T, et al:Early development of intractable epilepsy in children. A prospective study. Neurology 56(11):1445-1456, 2001.
PubMed
9) Picot M C, et al:The prevalence of epilepsy and pharmacoresistant epilepsy in adults:A population-based study in a Western European country. Epilepsia 49(7):1230-1238, 2008.
 
10) Annegers J F, et al:Risk of recurrence after an initial unprovoked seizure. Epilepsia 27(1):43-50, 1986.
PubMed
11) Berg A T, et al:Predictors of intractable epilepsy in childhood:A case-control study. Epilepsia 37(1):24-30, 1996.
PubMed
12) Stephen L J, et al:Does the cause of localization-related epilepsy influence the, response to antiepileptic drug treatment? Epilepsia 42(3):357-362, 2001.
PubMed
13) Dlugos D J, et al:Response to first drug trial predicts outcome in childhood temporal lobe epilepsy. Neurology 57(12):2259-2264, 2001.
PubMed
14) Brodie M J, et al:Staged approach to epilepsy management. Neurology 58(Suppl 5):S2-S8, 2002.
PubMed
15) Schuele S, et al:Intractable epilepsy:management and therapeutic alternatives. Lancet Neurol 7(6):514-524, 2008.
PubMed
16) Smith D, et al:The misdiagnosis of epilepsy and the management of refractory epilepsy in a specialist clinic. Q J Med 92(1):15-23, 1999.
 
17) Mizrahi E:Avoiding the pitfalls of EEG interpretation in childhood epilepsy. Epilepsia 37(Suppl.1):S41-S51, 1996.
 
18) Perucca E, et al:Antiepileptic drugs as a cause of worsening seizures. Epilepsia 39(1):5-17, 1998.
PubMed
19) Rho J:The pharmacologic basis of antiepileptic drug action. Epilepsia 40(11):1471-1483, 1999.
PubMed
20) Benbadis SR, et al:When drugs don't work. an algorithmic approach to medically intractable epilepsy. Neurology 55(2 of 2):1780-1784, 2000.
 
P.183 掲載の参考文献
1) Meierkord H, et al:Non-convulsive status epilepticus in adults:clinical forms and treatment. Lancet Neurol 6:329-339, 2007.
PubMed
2) 日本神経学会:てんかん重積状態,てんかん治療ガイドライン追補版2012 (印刷中)
 
3) Commission on classification and Terminology of the International League Against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 22:489-501, 1981.
PubMed
4) Riviello Jr J J, et al:Practice parameter:Diagnostic assessment of the child with status epilepticus (an evidence-based review). Neurology 67:1542-1550, 2006.
 
5) Treiman D M, et al:A comparison of four treatments for generalized convulsive status epilepticus. N Engl J Med 339:792-798, 1998.
PubMed
6) Alldredge B K, et al:A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus. N Engl J Med 345:631-637, 2001.
PubMed
7) Hesdorffer D C, et al:Incidence of status epilepticus in Rochester, Minnesota, 1965-1984. Neurology 50:735-741, 1998.
PubMed
8) Minicucci F, et al:Treatment of status epilepticus in adults:guidelines of the Italian League against Epilepsy. Epilepsia 47:9-15, 2006.
PubMed
9) DeLorenzo R J, et al:Aprospective population-based epidepmiologic study of status epilepticus in Richmond, Virginia. Neurology 46:1029-1035, 1996.
 
10) Remy C, et al:Intrarectal diazepam inpileptic adults. Epilepsia 33:353-358, 1992,
PubMed
11) Scott R C, et al:Buccal midazolam and rectaldiazepam for treatment of prolongedeizures in children and adolescence:a randomized trials. Lancet 353:623-626, 1999.
 
12) Working group on status epilepticus:Recommendations of the epilepsy foundation of America's working group on status epilepticus. JAMA 270:854-859, 1993.
 
13) Leppik I E, et al:Double-blind study of lorazepam and diazepam in status epilepticus. JAMA 249:1452-1454, 1983.
PubMed
14) 大澤真木子,他:けいれん重積の治療ガイドイン. 小児内科38:236-243, 2007.
 
15) Meierkord H, et al:EFNS guideline on yhranagement of status epilepticus in adults. Eur J Neurol 17:348-355, 2010.
PubMed
16) Rossetti A O, et al:Refractory statuspilepticus, Effect of treatment aggressiveness. Arch Neurol 62:1698-1702, 2005.
PubMed
17) Parviainen I, et al:Propofol and barbiturates for the anesthesia of refractory convulsive status epilepticus:pros and cons. Neurol Res 29:667-671, 2007.
PubMed
18) van Gestel J p J, et al:Propofol and thiopental for refractory SE in children. Neurology 65:591-592, 2005.
 
19) Meierkord H, et al:Non-convulsive status epilepticus in adults:clinical forms and treatment. Lancet Neurol 6:329-339, 2007.
PubMed
P.192 掲載の参考文献
1) Farwell J R, et al:Phenobarbital for febrile seizures-effects on intelligence and on seizure recurrence. N Engl J Med 322:364-369, 1990.
PubMed
2) Loring D W, et al:Topiramate dose effects on cognition:arandomized double-blind study. Neurology 76:131-137, 2011.
 
3) Messenheimer J A, et al:Safety review of adult clinical trial experience with lamot-rigine. Drug Safety 18:281-296, 1998.
 
4) Zaccara G, et al:Idiosyncratic adverse reactions to antiepileptic drugs. Epilepsia 48:1223-1244, 2007.
PubMed
5) Franciotta D, et al:Genetic basis for idiosyncratic reactions to antiepileptic drugs. Curr Opin Neurol 22:144-149, 2009.
PubMed
6) Shiohara T, et al:Drug-induced hypersen-sitivity syndrome (DIHS):a reaction in-duced by a complex interplay among herpesviruses and antiviral and antidrug immune responses. Allergol Int 55:1-8, 2006.
 
7) Kennedy G M, et al:CNS adverse events associated with antiepileptic drugs. CNS Drugs 22:739-760, 2008.
PubMed
8) 小出泰道, 他:ガバペンチンによるミオクローヌスの発現/増悪.自験162例の後方視的研究.臨神経49:342-347, 2009.
 
9) Abtahi M A, et al:Topiramate and the vision:a systematic review. Clin Ophthalmol 6:117-131, 2012.
 
10) Kim S C, et al:Hypohidrosis-related symptoms in pediatric epileptic patients with topiramate. Pediatr Int 52:109-112, 2010.
PubMed
11) Low P A, et al:Zonisamide and associated oligohidrosis and hyperthermia. Epilepsy Res 62:27-34, 2004.
PubMed
12) Jain K K:Systemic lupus erythematosus (SLE)-like syndromes associated with carbamazepine therapy. Drug Saf 6:350-360, 1991.
PubMed
13) 村上博和, 他:ポルフィリン症と投与禁忌薬物.日臨 53:1491-1497, 1995.
Medical*Online
14) Misra U K, et al:Management of provoked seizure. Ann Indian Acad Neurol 14:2-8, 2011.
PubMed
15) Ben-Menachem E:Weight issues for people with epilepsy-a review. Epilepsia 48 (Suppl 9):42-45, 2007.
 
16) 米田栄吉:薬物性歯肉増殖症の発症機序を探る.日歯周誌 44:315-321, 2001.
 
17) Mattson R H, et al:Barbiturate-related connective tissue disorders. Arch Intern Med 149:911-914, 1989.
PubMed
18) Shorvon S D, et al:Anticonvulsant peripheral neuropathy:a clinical and electrophysiological study of patients on single drug treatment with phenytoin, carbamazepine or barbiturates. J Neurol Psychiatry 45:620-626, 1982.
PubMed
19) Bauer J:Seizure-inducing effects of antiepileptic drugs:a review. Acta Neurol Scand 94:367-377, 1996.
PubMed
20) Tassinari C A, et al:Tonic status epilepticus precipitated by intravenous benzodiazepine in five patients with Lennox-Gastaut syndrome. Epilepsia 13:421-435, 1972.
PubMed
21) Livingston J H, et al:Non-convulsive status epilepticus resistant to benzodiazepines. Arch Dis Child 62:41-44, 1987.
PubMed
22) Dinnerstein E, et al:Lamotrigine intoxication provoking status epilepticus in an adult with localization-related epilepsy. Arch Neurol 64:1344-1346, 2007.
 
23) Cerminara C, et al:Lamotrigine-induced seizure aggravation and negative myoclonus in idiopathic rolandic epilepsy, Neurology 63:373-375, 2004.
PubMed
P.200 掲載の参考文献
1) Winterbottom J, et al:The effectiveness of preconception counseling to reduce adverse pregnancy outcome in women with epilepsy:What's the evidence? Epilepsy Behav 14(2):273-279, 2009.
PubMed
2) Winterbottom J B, et al:Preconception counselling for women with epilepsy to reduce adverse pregnancy outcome. Cochrane Database Syst Rev 16(3):CD006645, 2008.
 
3) 兼子直他:てんかんを持つ妊娠可能な女性に関する治療ガイドライン.日本てんかん学会ガイドライン作成委員会報告. てんかん研 25(1):27-31, 2008.
 
4) Meadora K, et al:Pregnancy outcomes in women with epilepsy:A systematic review and meta-analysis of published pregnancy registries and cohorts. Epilepsy Res 81(1):1-13, 2008
 
5) Holmes L B, et al:The AED (antiepileptic drug) pregnancy registry:a 6-year experience. Arch Neurol 61(5):673-678, 2004.
PubMed
6) Montouris G:Importance of monotherapy in women across the reproductive cycle. Neurology 69 (24Suppl 3):S10-S16, 2007.
 
7) Vinten J, et al:The behavioral consequences of exposure to antiepileptic drugs in utero. Epilepsy Behav 14(1):197-201, 2009.
PubMed
8) Morrow J, et al:Malformation risks of antiepileptic drugs in pregnancy:a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 77(2):193-198, 2006.
 
9) 厚生省保健医療局地域保健・健康増進栄養課生活習慣病対策室:神経管閉鎖障害の発症リスク低減のための妊娠可能な年齢の女性等に対する葉酸の摂取に係る適切な情報提供の推進についてhttp://wwwl.mhlw.go.jp/houdou/1212/h1228-1_18.html (2012/02/12 閲覧可能)
 
10) Roste L S, et al:Women and epilepsy:review and practical recommendations. Expert Rev 7(3):289-300, 2007.
PubMed
11) 兼子 直, 他:精神科における"てんかん"の診方:てんかんと妊娠.精神科治療 18(2):123-128, 2003.
 
12) Kaplan P W, et al:Obstetric risks for women with epilepsy during Pregnancy. Epilepsy Behav 11(3):283-291, 2007.
PubMed
13) Meador KJ, et al:HOPE Work Group. Pregnancy registries in epilepsy:a consensus statement on health outcomes. Neurology 71(14):1109-1117, 2008,
PubMed
14) Tomson T, et al:Collaborative EURAP Study Group. EURAP:an international registry of antiepileptic drugs and pregnancy. Epilepsia 45(11):1463-1464, 2004.
 
15) 兼本浩祐, 他:妊娠時のてんかん治療神経内科61(1):40-43, 2004.
 
16) EURAP Study Group. Seizure control and treatment in pregnancy:observations from the EURAP epilepsy pregnancy registry. Neurology 66(3):354-360, 2006.
 
17) Katz J M, et al:Primary generalized epilepsy:a risk factor for seizures in labor and delivery? Seizure 12(4):217-219, 2003.
PubMed
18) 日本神経学会監, てんかん治療ガイドライン作成委員会編:てんかん治療ガイドライン2010.医学書院東京, 2010.
 
19) Bromley R L, et al:Cognitive and neurodevelopmental effects of antiepileptic drugs. Epilepsy Behav 22(1):9-16, 2011.
PubMed
P.207 掲載の参考文献
1) Kanemoto K:Postictal psychoses, established facts and new clinical questions. In:The Neuropsychiatry of epilepsy, 2nd edition (Trimble M, et al, eds). pp67-79. Cam-bridge University Press, Cambridge, 2011.
 
2) 兼本浩祐, 他:てんかんと精神症状.医のあゆみ232:1086-1091, 2010.
 
3) 兼本浩祐, 他:てんかんに伴う精神症状・行動障害の治療. Brain Nerve 63:371-377, 2011.
 
4) Kanemoto K, et al:Does psyhosis of epilepsy differ from primary psychotic disorder? In:Controversies in psychiatric aspects ofepilepsy(Kanner AM, et al, eds). pp111-127. Elsvier, New York, 2008.
 
5) 兼本浩祐, 他:てんかんに関連する精神障害の治療法.モダンフィジシャン3:337-340, 2012.
 
P.216 掲載の参考文献
1) 伊藤進他:小児難治性てんかんに対するケトン食療法-「最後の選択肢」から「早期からの選択肢」へ. Brain Nerve 63(4):393-400, 2011.
 
2) Levy R G, et al:Ketogenic diet and otherdietary treatments for epilepsy. Cochrane Database Syst Rev 3:CD001903, 2012.
PubMed
3) Vining E P, et al:A multicenter study of the efficacy of the ketogenic diet. Arch Neurol 55(11):1433-1437, 1998.
PubMed
4) Neal E G, et al:The ketogenic diet for the treatment of childhood epilepsy:a randomised controlled trial. Lancet Neurol 7(6):500-506, 2008.
PubMed
5) Neal E G, et al:A randomized trial of classical and medium-chain triglyceride ketogenic diets in the treatment of childhood epilepsy. Epilepsia 50(5):1109-1117, 2009.
PubMed
6) Huttenlocher P R, et al:Medium-chain triglycerides as a therapy for intractable childhood epilepsy. Neurology 21(11):1097-1103, 1971.
PubMed
7) Kossoff E H, et al:Efficacy of the Atkins diet as therapy for intractable epilepsy. Neurology 61(12):1789-1791, 2003.
PubMed
8) Pfeifer H H, et al:Low-glycemic-index treatment:a liberalized ketogenic diet for treatment of intractable epilepsy. Neurology 65(11):1810-1812, 2005.
PubMed
9) Kossoff E H, et al:Optimal clinical management of children receiving the ketogenic diet:recommendations of the International Ketogenic Diet Study Group. Epilepsia 50(2):304-317, 2009.
 
10) Kossoff E H, et al:A modified Atkins diet is effective for the treatment of intractable epediatric epilepsy. Epilepsia 47(2):421-424, 2006.
 
11) Kossoff E H, et al:A prospective study of the modified Atkins diet for intractable epilepsy in adults. Epilepsia 49(2):316-319, 2008.
PubMed
12) Kossoff E H, et al:A randomized, crossover comparison of daily carbohydrate Units using the modified Atkins diet Epilepsy Behav 10(3):432-436, 2007.
 
13) Muzykewicz D A, et al:Efficacy, safety,and tolerability of the low glycemic indextreatment in pediatric epilepsy. Epilepsia 50(5):1118-1126, 2009.
PubMed
14) Ma W et al:Ketogenic diet metabolites reduce firing in central neurons by opening K(ATP)channels. J Neurosci 27(14):3618-3625, 2007.
PubMed
15) Stafstrom C E, et al:Anticonvulsant and antiepileptic actions of 2-deoxy-D-glucosein epilepsy models. Ann Neurol 65(4):435-447, 2009.
 
16) Xiao Y, et al:Poly unsaturated fatty acids modify mouse hippocampal neuronal excitability during excitotoxic or convulsant stimulation. Brain Res 846(1):112-121, 1999.
PubMed
17) Juge N, et al:Metabolic control of vesicular glutamate transport and release. Neuron 68(1):99-112, 2010.
PubMed
18) Ketogenic diets:Treatments for epilepsy and other disorders.5th ed (Kossoff E H, etal, eds), Demos Medical Publishing, New York, 2011.
 
19) 丸山博監:ケトン食の本-奇跡の食事療法.第一出版,東京, 2010.
 
20) 藤井達哉編:ケトン食の基礎から実践まで.診断と治療社,東京, 2011.
 
P.225 掲載の参考文献
1) 三原忠紘他:てんかん外科の適応に関するガイドライン.てんかん研26:114-118, 2008.
 
2) Engel J Jr, et al:Surgically remediable syndromes. In:Epilepsy;A Comprehensive Textbook 2nd. ed (Engel J Jr, et al, eds),pp1761-1769. Lippencott Williams & Wilkins, Philadelphia 2007.
 
3) Kameyama S, et al:Minimally invasive magnetic resonance imaging-guided stereotactic radio frequency thermocoagulation for epileptogenic hypothalamic hamartomas. Neurosurgery 65:438-449, 2009.
 
4) Wiebe S, et al:A randomized, controlled trial of surgery for temporal-lobe epilepsy. N Engl JMed 345:311-318, 2001.
 
5) Blufmcke I, et al:The clinicopathologic spectrum of focal cortical dysplasias:a consensus classification proposed by an ad hoc Task Force of the ILAE Diagnostic Methods Commission. Epilepsia 52:158-174, 2011.
 
6) Widjaja E, et al:Cost-effectiveness of pediatric epilepsy surgery compared to medical treatment in children with intractable epilepsy. Epilepsy Res 94:61-68, 2011.
PubMed
7) 亀山茂樹他:新皮質てんかんの外科治療ガイドライン.てんかん研23:167-170, 2005.
 
8) Tao J X, et al:Cortical substrates of scalp EEG epileptiform discharges. J Clin Neurophysiol 24:96-100, 2007.
PubMed
9) Oishi M, et al:Epileptic spikes:magnetoencephalography versus simultaneous electrocorticography. Epilepsia 43:1390-1395, 2002.
PubMed
10) von Oertzen TJ, et al:Prospective use of subtraction ictal SPECT coregistered to MRI (SISCOM)in presurgical evaluation of epilepsy. Epilepsia 52:2239-2248, 2011.
PubMed
11) Cukiert A, et al:Seizure's outcome after cortical resections including the face and tongue rolandic areas in patients with refractory epilepsy and normal MRI submitted to subdural grids' implantation. Arq Neuropsiquiatr 59:717-721, 2001.
 
12) Morrell F, et al:Multiple subpial transection:a new approach to the surgical treatment of focal epilepsy. J Neurosurg 70:231-239, 1989.
 
13) Delalande O, et al:Vertical parasagittal hemispherotomy:surgical procedures and clinical long-term outcomes in a population of 83 children. Neurosurgery 60(2 Suppl 1):ONS19-32, 2007.
 
14) 馬場啓至:てんかん診療最前線難治性てんかんに対する脳梁離断術とその手術適応近の動向. Epilepsy 5:129-134, 2011.
 
15) Engel J Jr, et al:Outcome with respect topileptic seizures. In:Surgical treatment of the epilepsies, second edition (Engel J Jr,d), pp609-621. Raven Press, New York, 1993.
 
P.233 掲載の参考文献
1) Lesser R P:Unexpected places:how did vagus nerve stimulation become a treatment for epilepsy? Neurology 52:1117-1118, 1999.
PubMed
2) Fisher R S, et al:Reassessment:vagus nerve stimulation for epilepsy:a report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 53:666-669, 1999.
PubMed
3) 川合謙介:難治性てんかんに対する迷走神経刺激療法の現状 Jpn J Neurosurg 16:194-202, 2007.
 
4) Ben-Menachem E:Vagus-nerve stimulation for the treatment of epilepsy. Lancet Neurol 1:477-482, 2002.
 
5) Elliott R E, et al:Vagus nerve stimulation in 436 consecutive patients with treatment-resistant epilepsy:long-term outcomes and predictors of response. Epilepsy Behav 20:57-63, 2011.
PubMed
6) The-Vagus-Nerve-Stimulation-Study-Group:A randomized controlled trial ofchronic vagus nerve stimulation for treatment of medically intractable seizures. The Vagus Nerve Stimulation Study Group. Neurology 45:224-230, 1995.
 
7) Handforth A, et al:Vagus nerve stimulation therapy for partial onset seizures:a randomized active control trial. Neurology 51:48-55, 1998.
PubMed
8) Morris G L 3rd, et al:Long-term treatment with vagus nerve stimulation in patients with refractory epilepsy. The Vagus Nerve Stimulation Study Group E01-E05. Neurology 53:1731-1735, 1999.
 
9) Elliott R E, et al:Vagus nerve stimulation for children with treatment-resistant epilepsy:a consecutive series of 141 cases. J Neuro surg Pediatr 7:491-500, 2011.
 
10) McLachlan R S, et al:Quality of life after vagus nerve stimulation for intractable epilepsy:is seizure control the only contributing factor? Eur Neurol 50:16-19, 2003.
PubMed
11) Malow B A, et al:Vagus nerve stimulation reduces daytime sleepiness in epilepsy patients. Neurology 57:879-884, 2001.
PubMed
12) Clark K B, et al:Enhanced recognition memory following vagus nerve stimulation in human subjects. Nat Neurosci 2:94-98, 1999.
PubMed
13) Elger G, et al:Vagus nerve stimulation is associated with mood improvements in epilepsy patients. Epilepsy Res 42:203-210, 2000.
PubMed
14) Harden C L, et al:A Pilot Study of Mood in Epilepsy Patients Treated with Vagus Nerve Stimulation. Epilepsy Behav 1:93-99, 2000.
 
15) Zamponi N, et al:Vagus nerve stimulation (VNS) is effective in treating catastrophic epilepsy in very young children. Neurosurg Rev 31:291-297, 2008.
PubMed
16) McGregor A, et al:Right-sided vagus nerve Stimulation as a treatment for refractory epilepsy in humans. Epilepsia 46:91-96, 2005.
PubMed
17) Annegers J F, et al:Epilepsy, vagal nerve stimulation by the NCP system, all-cause mortality, and sudden, unexpected, unexplained death. Epilepsia 41:549-553, 2000.
PubMed
18) Zagon A, et al:Slow hyperpolarization incortical neurons:a possible mechanism behind vagus nerve simulation therapy for refractory epilepsy? Epilepsia 41:1382-1389, 2000.
 
19) Di Lazzaro V, et al:Effects of vagus nerve stimulation on cortical excitability in epileptic patients. Neurology 62:2310-2312, 2004.
PubMed
20) Biggio F, et al:Chronic vagus nerve stimulation induces neuronal plasticity in the rat hippocampus. Int J Neuropsychophamacol 12:1209-1221, 2009.
 
P.242 掲載の参考文献
1) Kwan P, et al:The natural history of epilepsy:an epidemiological view. J Neurol Neurosurg Psychiatry 75:1376-1381, 2004.
 
2) Schmidt D, et al:Evidence-based review on the natural history of the epilepsies. Curr Opin Neurol 25:159-163, 2012.
PubMed
3) Placencia M, et al:Antiepileptic drug treatment in a community health care setting in northern Ecuador:aprospective 12-month assessment. Epilepsy Res 14:237-244, 1993.
 
4) Watts A E, et al:The natural history of untreated epilepsy in a rural community in Africa. Epilepsia 33:464-468, 1992.
 
5) Feksi A T, et al:Comprehensive primary health care anti epileptic drug treatment programme in rural and semi-urban Kenya. ICBERG (International Community-based Epilepsy Research Group). Lancet 337:406-409, 1991.
PubMed
6) Rodin E A:The prognosis of patients with epilepsy. Illinois:Charles C Thomas, 1968.
 
7) Reynolds E H:Early treatment and prognosis of epilepsy. Epilepsia 28:97-106,1987.
PubMed
8) Cockerell O C, et al:Remission of epilepsy:results from the National General Practice Study of Epilepsy. Lancet 346:140-144, 1995.
PubMed
9) Sillanpaa M, et al:Long-term prognosis of seizures with onset in childhood. N Engl J Med 338:1715-1722,1998.
PubMed
10) Sillanpaa M, et al:Early seizure frequency and aetiology predict long-term medical outcome in childhood-onset epilepsy. Brain 132:989-998,2009.
PubMed
11) Tomson T:Mortality in epilepsy. J Neurol 247:15-21,2000.
 
12) Shorvon S, et al:Sudden unexpected death in epilepsy. Lancet 378:2028-2038,2011.
PubMed
13) Cockerell O C, et al:Mortality from epilepsy:results from a prospective population-based study. Lancet 344:918-921, 1994.
PubMed
14) Neligan A, et al:The long-term risk of premature mortality in people with epilepsy. Brain 134:388-395,2011.
 
15) Sillanpaa M, et al:Long-term mortality in childhood-onset epilepsy. N Engl J Med 363:2522-2529,2010.
PubMed
16) Kwan P, et al:Early identification of refractory epilepsy. N Engl J Med 342:314-319,20.
PubMed
17) Callaghan B, et al:Remission and relapse in a drug-resistant epilepsy population followed prospectively. Epilepsia 52:619-626, 2011.
 
18) Del Felice A, et al:Early versus late remission in a cohort of patients with newly diagnosed epilepsy. Epilepsia 51:37-42, 2010.
 
19) 日吉俊雄:日本てんかん学会ガイドライン作成委員会報告.成人てんかんの薬物治療終結のガイドライン.てんかん研27:417-422,2010.
 
20) 須貝研司:日本てんかん学会ガイドライン作成委員会報告.小児てんかんの薬物治療終結のガイドライン.てんかん研28:40-47,2010.
 
21) 日本神経学会てんかんの診療ガイドライン改定第2版.医学書院,東京,2010.
 
22) Schmidt D, et al:Uncontrolled epilepsy following discontinuation of anti epileptic drugs in seizure-free patients:a review of current clinical experience. Acta Neurol Scand 111:291-300,2005.
PubMed
23) Okuma T, et al:Natural history and prognosis of epilepsy:report of a multi-institutional study in Japan. The group for the study of prognosis of epilepsy in Japan. Epilepsia 22:35-53, 1981.
 
24) Wakamoto H, et al:Long-term medical, educational, and social prognoses of childhood-onset epilepsy:a population-based study in a rural district of Japan. Brain Dev 22:246-255, 2000.
 
P.250 掲載の参考文献
1) Shibahara S:The 2011 Tohoku earthquake and devastating tsunami. Tohoku J Exp Med 223(4):305-307, 2011.
PubMed
2) Rossetti A O, et al:Determinants of success in the use of oral levetiracetam in status epilepticus. Epilepsy Behav 8:651-654, 2006.
PubMed
3) 中里信和:てんかん診療への震災緊急対応と長期展望.東北大学医学系研究科・医学部東日本大震災記録集(柴原茂樹,他編),pp 183-184.東北大学医学系研究科・医学部,仙台市, 2012.
 
4) Epilepsy Action(http://www.epilepsy.org.uk/)
 
P.260 掲載の参考文献
1) 厚生労働省ホームページ(平成24年5月)
 
2) 久保田英幹:てんかんをこうしてなおそう.クリエイツかもがわ,京都, 2009.
 
3) 社会保障入門編集委員会:てんかんの人が使える制度一覧社会保障入門2011.p103-109.中央法規出版,東京, 2012.
 
P.270 掲載の参考文献
1) 日本てんかん学会法的問題検討委員会:道路交通法改正にともなう運転適性の判定について.てんかん研20:135-138, 2002.
 
2) 風祭元:てんかんと自動車運転適性.こころの科学159:10-15, 2011.
 
3) 西田拓司,他:てんかんと運転免許,臨精医34:1535-1540,2005.
 
4) Inoue Y, et al:Epilepsy and drving in Japan. Epilepsia 45:1630-1635, 2004.
 
5) 日本てんかん学会法的問題検討委員会:てんかんをもつ人における運転適性の判定指針.てんかん研19:140-141, 2001.
 
6) Advisory Board to the Driving Licence Committee of the European Union:Epilepsy and driving in Europe. Final Report, 2005.
 
7) International Epilepsy News. No.173, 2010.
 
8) Drazkowski J F, et al:Seizure-related motor vehicle crashes in Arizona before and after reducing the driving restriction from 12 to 3 months. Mayo Clin Proc 78:819-825, 2003.
PubMed
9) Zarroli K, et al:Employment after anterior temporal lobectomy. Epilepsia 52:925-931, 2011.
PubMed
10) McLachlan R S, et al:Impact of mandatory physician reporting on accident risk in epilepsy. Epilepsia 48:1500-1505, 2007.
PubMed
11) Salinsky M C, et al:Epilepsy, driving laws and patient disclosure to physicians, Epilepsia 33:469-472, 1992.
PubMed
12) Tatum W O, et al:Disobedience and driving in patients with epilepsy. Epilepsy Beh 23:30-35, 2011.
 
13) No Y J, et al:Factors contributing to driving by people with uncontrolled seizures. Seizure 20:491-493, 2011.
PubMed
14) Polychronopoulos P, et al:Factors associated with poor compliance of patients with epilepsy driving restrictions. Neurology 67:869-871, 2006.
PubMed
15) 日本てんかん学会法的問題検討委員会:てんかんのある人における運転免許の現状と問題点.てんかん研2012(印刷中)
 
16) ワークショプ:道路交通法改正後のてんかんをもつ人における運転免許.てんかん研22:60-67,2004.
 

第5章 ガイドライン

P.277 掲載の参考文献
1) てんかん治療ガイドライン作成委員会:てんかん治療ガイドライン2010, p1-154.医学書院,東京,2010.
 
2) http://onlinelibrary.wiley.com/journal/10.1111/%281SSN%291528-1167/homepage/virtual_issue_guidelines_and__special_reports.htm#other
 
3) http://www.aan_com/go/practice/guidelines
 
4) http://guidance.nice.org.uk/CG137
 
5) http://www.sign.ac.uk/guidelines/fulltext/70/index.html
 
6) http://www.hkmj.org/supplements/article_pdfs/hkm0910spsp6.pdf
 

書評

最近チェックした商品履歴

Loading...